Try our Advanced Search for more refined results
Foster Murphy
-
Response | Filed: February 20, 2024 | Entered: February 21, 2024 FOSTER, MURPHY, ALTMAN & NICKEL, PC v. ASCLETIS PHARMA, INC. et al
Contract: Other | District Of Columbia
Surreply
SURREPLY to re Order on Motion for Leave to File, filed by FOSTER, MURPHY, ALTMAN & NICKEL, PC. (Attachments: # 1 Exhibit)(zdp)
-
Order | Filed: February 20, 2024 | Entered: February 20, 2024 FOSTER, MURPHY, ALTMAN & NICKEL, PC v. ASCLETIS PHARMA, INC. et al
Contract: Other | District Of Columbia
Order on Motion for Leave to File
MINUTE ORDER granting 25 Motion for Leave to File Surreply. The Clerk of the Court is directed to docket plaintiff's surreply [25-1] and attached exhibit [25-2] on the docket. No further pleadings may be submitted by either party with respect to the pending motion unless and until they are solicited by the Court. SO ORDERED. Signed by Judge Amy Berman Jackson on 2/20/2024. (lcabj1)
-
Response | Filed: February 20, 2024 | Entered: February 20, 2024 FOSTER, MURPHY, ALTMAN & NICKEL, PC v. ASCLETIS PHARMA, INC. et al
Contract: Other | District Of Columbia
Memorandum in opposition to motion
Memorandum in opposition to re 25 Motion for Leave to File, Surreply filed by ASCLETIS BIOSCIENCE CO., LTD., ASCLETIS PHARMA, INC., ASCLETIS PHARMACEUTICALS CO., LTD., GANNEX PHARMA CO., LTD., JINZI JASON WU. (Attachments: # 1 Text of Proposed Order)(Mitchell, Thomas)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login